Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating
agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer
patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4
nodules are eligible. Tirapazamine will be given by intra-arterial injection before
embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat
treatment is necessary only if disease progression. Expansion cohorts are open for metastatic
gastrointestinal cancer and neuroendocrine tumor.